ArticleCureus2024
Clear Cell Carcinoma Arising From Adenomyotic Cyst: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ovarian endometriosis associated with significantly elevated CA19-9: a case report.Frontiers in oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell carcinoma often arises from endometriosis, primarily from ovarian chocolate cysts and much less frequently from adenomyosis. We herein report a case of clear cell carcinoma arising from adenomyotic cyst in a 38-year-old woman, gravida 0, para 0, who was referred to our department with a diagnosis of a uterine tumor. Her medical history was unremarkable. Contrast-enhanced magnetic resonance imaging revealed a 13-cm uterine tumor with a predominantly hypointense signal on both T1- and T2-weighted images, accompanied by a hyperintense lesion in the center on T1-weighted images. Additionally, typical uterine leiomyomas were observed. Her serum CA125 (reference range: 0-35 units/ml) and CA19-9 (reference range: 0-37 units/ml) levels were elevated to 1,200 and 8,178 U/mL, respectively. Degenerated myoma was suspected preoperatively. Given the patient's desire to preserve her fertility, a myomectomy was performed. Macroscopically, the tumor was solid, white, and fibroid-like but contained chocolate-colored fluid. Pathological examination revealed clear cell carcinoma characterized by adenocarcinoma cells with clear and eosinophilic cytoplasm and nuclear atypia arranged in a tubulocystic pattern. Endometriosis was also found within the tumor. Subsequently, a hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymphadenectomy were performed. No malignancy was detected in the resected uterus or adnexa, but metastasis to a para-aortic lymph node was observed. Based on these findings, the patient was diagnosed with stage IIIC2 endometrial cancer (pT1bN2M0, clear cell carcinoma) and received postoperative adjuvant therapy with paclitaxel and carboplatin. Eighteen months later, her serum CA125 increased to 45 U/mL, and a contrast-enhanced computed tomography scan revealed multiple liver and left supraclavicular lymph node metastases. Five cycles of pembrolizumab and lenvatinib followed by four cycles of doxorubicin and cisplatin were ineffective. The patient died 13 months after the diagnosis of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.